Lesion With Known or Suspected F-choline Uptake
Conditions
Keywords
Imaging, F-choline PET, Diagnostic performance
Brief summary
Choline is an important building block of phospholipids in cell membranes. Certain cancers and medical conditions are known to demonstrate increased absorption and incorporation of choline into their cell membranes. 18-F-fluorocholine (F-choline) and 11-C-choline (C-choline) are diagnostic positron emission tomography (PET) radiotracers that can be used to image, in vivo, the metabolism of choline. Both tracers have been extensively studied in prostate cancer and C-choline has obtained US FDA approval for the investigation of recurrent prostate cancer. F-choline is currently not approved for clinical use by the FDA or Health Canada, but it offers many advantages over C-choline due to its better physical characteristics (mainly due to its positron range, shorter and longer half-life). In recent years, reports have started to emerge on broader potential applications of choline PET imaging, particularly for imaging parathyroid adenomas, certain cervical cancers and certain liver cancers. The main objective is to discover and explore potential new and emerging indications in which F-choline could play a role and provide clinically relevant information. Secondary objectives are 1) To assess the safety of F-choline PET imaging using F-choline produced at the CRCHUM; 2) assess changes in patient/disease management following F-choline PET imaging. Researchers hypothesize that F-choline will provide useful and incremental clinical information in a variety of conditions, and outperform the "standard" workup in numerous conditions. F-Choline PET exams will be performed on hybrid PET/CT scanners according to standard procedures. These examinations could be repeated at the discretion of the treating physician (up to a maximum of 4 exams per year) if the treating physician and the research team deem this could provide additional clinically useful information (for example, by helping to assess response to newly started therapy). The results will be provided to the attending physician and any new knowledge could lead to a change in treatment or an investigation of the condition that prompted enrollment in the study.
Interventions
DRUGF-choline intravenous injection
Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
Sponsors
Centre hospitalier de l'Université de Montréal (CHUM)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any patient with a known or suspected condition in which F-choline PET imaging might provide clinically useful information.
Exclusion criteria
* Pregnancy * Breastfeeding woman, unwilling to discontinue breastfeeding for 48 hours * Known allergy to F-choline or any excipients * Pediatric patient (\< 18 years old)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance (sensitivity and specificity) of F-choline PET/CT | 3 months | "Gold-standard" will be a composite of other imaging modalities, pathological data when available, and clinical follow-up. |
| Adverse reaction to the F-choline injection | 24 hours | Absence or presence of adverse reactions related to F-choline injection (yes or no) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in management following F-choline PET/CT | 3 months | Frequency of change in management, comparing planned management before and after F-choline PET/CT |
Countries
Canada
Contacts
CONTACTDaniel Juneau, MD
PRINCIPAL_INVESTIGATORDaniel Juneau, MD
Centre hospitalier de l'Université de Montréal (CHUM)
Outcome results
None listed